FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 52 filers reported holding FUSION PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $27,777,851 | -44.2% | 10,683,789 | +0.5% | 0.07% | -40.3% |
Q2 2023 | $49,766,133 | +125.7% | 10,633,789 | +81.8% | 0.12% | +125.5% |
Q1 2023 | $22,051,107 | +117.1% | 5,849,100 | +81.4% | 0.06% | +96.4% |
Q4 2022 | $10,155,915 | +6.3% | 3,224,100 | +1.6% | 0.03% | 0.0% |
Q3 2022 | $9,555,000 | +22.8% | 3,174,100 | +1.6% | 0.03% | +33.3% |
Q2 2022 | $7,779,000 | -67.2% | 3,124,100 | +2.3% | 0.02% | -61.1% |
Q1 2022 | $23,738,000 | +261.6% | 3,055,037 | +94.1% | 0.05% | +350.0% |
Q4 2021 | $6,564,000 | -43.0% | 1,574,000 | +8.3% | 0.01% | -45.5% |
Q3 2021 | $11,514,000 | +138.4% | 1,453,890 | +143.2% | 0.02% | +144.4% |
Q2 2021 | $4,830,000 | -20.3% | 597,841 | +5.8% | 0.01% | -25.0% |
Q1 2021 | $6,057,000 | -1.8% | 565,000 | +7.6% | 0.01% | -7.7% |
Q4 2020 | $6,169,000 | +0.6% | 525,000 | +2.9% | 0.01% | -7.1% |
Q3 2020 | $6,130,000 | +9.7% | 510,000 | +59.4% | 0.01% | 0.0% |
Q2 2020 | $5,590,000 | – | 320,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ADAMS STREET PARTNERS LLC | 2,973,744 | $24,028,000 | 4.99% |
Pivotal bioVenture Partners Investment Advisor LLC | 1,598,377 | $12,613,000 | 4.97% |
Johnson & Johnson Innovation - JJDC, Inc. | 3,670,516 | $29,658,000 | 3.03% |
Sio Capital Management, LLC | 266,107 | $2,150,000 | 0.53% |
Orbimed Advisors | 3,224,770 | $26,056,000 | 0.26% |
Perceptive Advisors | 3,550,334 | $28,686,000 | 0.19% |
AlphaCentric Advisors LLC | 71,500 | $578,000 | 0.16% |
Rock Springs Capital Management LP | 948,327 | $7,662,000 | 0.15% |
TPG Group Holdings (SBS) Advisors, Inc. | 2,551,794 | $20,618,000 | 0.15% |
Artal Group S.A. | 750,000 | $6,060,000 | 0.12% |